Market Signal Briefing

Some might call them boring businesses, but they have tremendous dividend growth track records.

Dividends are one of investors' most powerful tools for earning strong returns over the long run. Buying shares of strong dividend-paying companies and reinvesting the payout allows compounding to work its magic. That's partly why, over the long run, dividend stocks have vastly outperformed non-paying counterparts. It also helps that corporations that can issue regular (and growing) payouts tend to have robust underlying businesses.

With that said, let's consider two outstanding dividend stocks that are worth holding on to for good: AbbVie (ABBV 4.45%) and Zoetis (ZTS +0.34%).

1. AbbVie
AbbVie, a well-known, leading pharmaceutical company, has many of the qualities of a forever stock. First, the products it sells will never go out of style, at least until we stumble upon a way to cure all diseases, which probably won't happen anytime soon. Second, AbbVie generates consistent revenue and earnings even in times of economic troubles. The company's portfolio of medicines spans immunology, oncology, neuroscience, and other areas. Many treat chronic, sometimes life-threatening, conditions.

One exception is AbbVie's Botox Cosmetic, a product people can choose to forgo without significant consequences when the economy is down. Still, its brand name makes it a perpetual leader in its niche. The broader point is that demand for AbbVie's medicines remains high when the going gets rough, and since insurance generally helps cover the costs, patients don't bear the full burden during economic recessions.

Today's Change

(

-4.45

%) $

-10.16

Current Price

$

218.04

Third, AbbVie has the innovative qualities and the deep pipeline necessary to survive patent cliffs. After expertly navigating the loss of patent exclusivity for Humira -- a medicine that generated $21.2 billion in annual sales at its peak -- a couple of years ago, AbbVie quickly returned to top-line growth and won't face another major patent cliff through the end of the decade at least.

The company's growth drivers, especially its immunology medicines Skyrizi and Rinvoq, should help it post excellent financial results through the mid-2030s at least. By then, the company will likely have found new gems to replace them.That's how pharmaceutical companies stay in business for a long time, and AbbVie has shown that it can follow this blueprint.

Then, there is the company's dividend record. AbbVie is a member of the Dividend Kings, a group of corporations that have raised their payouts for at least 50 straight years. AbbVie's own streak stands at 53. Overall, AbbVie looks like a reliable dividend payer that should continue to perform well and reward shareholders for a long time. The stock is a great forever pick for dividend seekers.

2. Zoetis
Zoetis is a leading animal health company. Its products span multiple categories, including poultry, companion animals, and fish. Zoetis also sells a variety of products for these animals. It boasts about 300 brands, with 17 of its products generating over $100 million in annual revenue. However, the company's most important long-term opportunity lies within its companion animal category, where it already generates most of its sales. There are several reasons for that.

The company's livestock segment, for instance, is cyclical. Demand for animal protein can dip significantly due to economic conditions. Other factors, sometimes unpredictable ones (such as disease outbreaks), can affect it.

In contrast, the company's companion animal unit is more stable. There is consistent demand for products to care for dogs and cats. This mirrors the recurring prescriptions people receive, which force them to refill medicines at regular intervals. And since many owners consider their pets family members, they are more than willing to pay for them.

Today's Change

(

0.34

%) $

0.49

Current Price

$

144.09

Partly thanks to its strong performance in the companion animal category, Zoetis has remained a leader in the animal health niche, generally generating stronger revenue and earnings growth than the average, while consistently innovating and launching newer products. Over the long run, we can expect this segment to perform well as pet ownership continues to rise.

Lastly, looking at Zoetis' dividend track record, the company has increased its payouts by 502.4% over the past 10 years. Zoetis is a dream come true for income-oriented investors focused on the long game.

Viking's stock surged in one trading session after a positive clinical trial report last year.

Viking Therapeutics (VKTX 0.37%) leaped onto center stage early last year when it announced promising news about a candidate addressing an area of soaring demand: weight loss. The biotech then said its weight loss candidate, VK2735, met the goals of its phase 2 study. Investors realized it would be continuing into later-stage trials -- and the stock price surged more than 120% in one trading session.

Viking remains on track, with the injectable candidate in phase 3 trials and an oral version now in phase 2. As for the stock price, it lost momentum and fell 47% over the past year. But in recent times, the positive momentum has gained some ground. The shares have climbed about 16% over the past three months.

Now, heading into the first week of November, Viking faces a couple of potential catalysts. Should you buy the stock before Nov. 5 to possibly benefit? Let's find out.

Image source: Getty Images.

Viking's weight loss candidate
First, let's take a quick look at Viking's ups and downs over the past year or so. The company's VK2735 falls into the same category of drugs as those dominating the weight loss market today. These are GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists such as those made by pharma giants Novo Nordisk and Eli Lilly. These types of drugs act on hormones involved in the digestion process and, as a result, help control blood sugar levels and appetite.

Though Novo Nordisk and Lilly already dominate the market, demand is so great for these products that there's room for others to enter -- and potentially generate blockbuster revenue down the road. Viking, with a candidate in phase 3 trials right now, could reach the finish line within the next few years if all goes smoothly. The candidate in its phase 2 study showed up to 13.1% average weight loss after 13 weeks -- and researchers didn't observe a plateau, which means patients may continue to lose weight after that period.

Today's Change

(

-0.37

%) $

-0.14

Current Price

$

38.03

Viking versus Novo Nordisk and Eli Lilly
It's impossible to compare Viking's candidate with the Novo Nordisk and Lilly drugs since each trial design is different -- and the pharmaceutical companies' drugs today are being used in the real world. But Viking's trial results are solid and suggest it could clearly find a spot in the weight loss market -- a market that analysts say may approach $100 billion by the end of this decade.

Though Viking shares have declined from their peak and spent some time in the doldrums, this isn't based on any bad news from the company. Reasons for the stock price movement could be many, from some investors locking in profits to disappointment that the company hasn't been acquired by a bigger player seeking access to the obesity market. The positive point here is that these reasons don't support a sell case for this stock.

Now, let's consider the potential catalysts coming up this week -- and whether you should buy the stock before Nov. 5.

Presentations this week
Viking is set to make poster presentations about VK2735 at two medical conferences this week. At ObesityWeek 2025, the company will make two poster presentations, scheduled for Nov. 5 and 6. One will cover how VK2735 impacted prediabetes and metabolic syndrome in the phase 2 study, and the other will detail the design of the company's phase 3 study in patients with obesity and at least one weight-linked health problem.

Later in the week, at the American Heart Association Scientific Sessions 2025, Viking's poster presentations will feature the design of the phase 3 study in type 2 diabetes patients who are also overweight and a look at the company's research into the frequency of cardiometabolic conditions across body mass index levels.

The data could reinforce the importance of VK2735 and other drugs in its class, and that may support optimism about the candidate and Viking in general. Weight loss drugs linked to the reduction of other health problems have an easier road to reimbursement, so these observations shouldn't be overlooked.

Still, since this isn't a trial report or update like the one that drove massive gains early last year, I wouldn't expect enormous stock price movement.

All this means that Viking is a great biotech buy -- its candidate is promising, you can benefit from getting in on the dip, and momentum has been picking up. But you don't have to rush to scoop up this player before Nov. 5. Instead, you can take your time and leisurely build up a position.

NEW YORK, Nov. 02, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Baxter International Inc. (NYSE: BAX) between February 23, 2022 and July 30, 2025, both dates inclusive (the “Class Period”), of the important December 15, 2025 lead plaintiff deadline.

SO WHAT: If you purchased Baxter common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Baxter class action, go to https://rosenlegal.com/submit-form/?case_id=17664 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 15, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants misled investors by failing to disclose that: (1) the Novum IQ Large Volume Pump (“Novum LVP”) suffered systemic defects that caused widespread malfunctions, including underinfusion, overinfusion, and complete non-delivery of fluids, which exposed patients to risks of serious injury or death; (2) Baxter was notified of multiple device malfunctions, injuries, and deaths from these defects; (3) Baxter’s attempts to address these defects through customer alerts were inadequate remedial measures, when design flaws persisted and continued to cause serious harm to patients; (4) as a result, there was a heightened risk that customers would be instructed to take existing Novum LVPs out of service and that Baxter would completely pause all new sales of these pumps; and (5) based on the foregoing, Baxter’s statements about the safety, efficacy, product rollout, customer feedback and sales prospects of the Novum LVPs were materially false and misleading. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Baxter class action go to https://rosenlegal.com/submit-form/?case_id=17664 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com

The semiconductor company is getting its footing with new management at the helm.

Intel (INTC 0.32%) is officially up 100% this year. The forgotten semiconductor giant is regaining its footing after receiving investments from both Nvidia and the United States government, while also splitting off a subsidiary named Altera. With a cleaned-up balance sheet and earnings momentum, Intel's cash burn has begun to stabilize, with plans to increase its manufacturing capacity in the U.S. as a part of its reshoring strategy.

Today, Intel trades at a market cap of just $200 billion, compared to Nvidia approaching $5 trillion. Does that make Intel stock a buy, with good news finally arriving for the computer chip company? Let's take a closer look and find out.

Today's Change

(

-0.32

%) $

-0.13

Current Price

$

40.03

Nvidia and government investments
After a decade of missteps, Intel has officially lost its position as the top manufacturer of advanced semiconductors for computers, smartphones, and data centers. Artificial intelligence (AI) spending has further deepened this divide. Data centers are now being filled with computer chips from Nvidia and other semiconductor companies instead of from Intel, whose designs have fallen behind the pack.

Since the end of 2022, Intel has been burning cash to try to catch up in semiconductor design and to invest in its own semiconductor foundry to compete with Taiwan Semiconductor Manufacturing. A foundry is a manufacturing plant for semiconductors where a company makes third-party designs for customers. Historically, Intel simply manufactured its own chips, but it has since fallen behind in capabilities to its Taiwanese competition.

At the start of this year, investors had counted Intel out, expecting it to keep losing ground to Taiwan Semiconductor and Nvidia. However, Intel's fortunes have begun to change. It brought on new CEO Lip-Bu Tan, a semiconductor design veteran. He then proceeded to sell a stake in Altera, a chip subsidiary for programmable design, for $4.46 billion to raise funds.

Later in the summer, the U.S. government took a strategic stake in Intel as a national champion in semiconductor manufacturing, while Nvidia invested $5 billion into the company. These funds will be used to help Intel invest for the future of AI semiconductor manufacturing in the U.S., giving it a better footing to compete without worrying about its balance sheet. This is why Intel stock is up significantly in recent months, rewarding shareholders who bet on the storied brand in one of its darkest moments.

Image source: Getty Images.

Will it split off the foundry?
We can think of Intel as two businesses. There's the integrated design and manufacturing of its own computer chips, which we can call the legacy business model. Last quarter, Intel's combined segments from this legacy business -- including personal computing and data center sales -- generated $12.6 billion in revenue and $3.7 billion in segment operating income. That's a respectable business, but one still significantly behind Nvidia in terms of scale and profitability.

Then, we have the foundry business. It does a measly $4.2 billion in revenue, and it actually lost $2.3 billion last quarter. Intel needs more scale in manufacturing computer chips for other companies before it can generate a profit, which is the main reason the company has negative free cash flow at the moment. A key issue preventing growing demand for Intel's foundry business is that its potential customers compete with Intel's own computer chips when selling into data center deployments.

With this conflict of interest, analysts have proposed that Intel split up its chip design and manufacturing businesses into two separate companies, using the profits and cash flow generated by the chip design business to capitalize the foundry manufacturing business as it scales up. This would make it more palatable for customers to sign up with the Intel foundry, while giving it a balance sheet capable of surviving years of cash burn as it scales up its factories.

It's unclear whether a plan for this is in the works, but it could help the combined design and foundry businesses grow earnings over the long haul.

Is Intel stock a buy today?
With a market value of $200 billion, Intel trades at a price-to-earnings multiple of 15 -- if we exclude the money-losing foundry business and simply look at the segment earnings from its personal computer and data center sales. This is a reasonable earnings multiple, especially if you think Intel will start to catch up to competitors like Nvidia over the next decade.

However, that still leaves investors with the foundry business burning a hole in Intel's pocket. Add this subsidiary into the mix, and Intel's stock looks much more expensive on trailing earnings, and risky. If you're a believer in the long-term growth of Intel's foundry and the potential split from its design business, the stock is a buy. But if you think it will stay behind Taiwan Semiconductor forever, then it's best to avoid adding after this massive run-up.

Analyst’s Disclosure:I/we have a beneficial long position in the shares of BTE either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Disclaimer: I am not an investment advisor and this is not a recommendation to buy or sell a security. Investors are recommended to read all of the company's filings and press releases as well as do their own research to determine if the company fits their own investment objectives and risk portfolios.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Donation to help accelerate relief as the island's communities face widespread devastation

, /PRNewswire/ -- Lowe's today announced a $1 million donation to support hurricane recovery and rebuilding efforts in Jamaica after the devastating impact of Hurricane Melissa earlier this week. As a part of the company's long-standing commitment to helping communities when they need it most, the donation will provide grants and product donations to nonprofit relief partners.

"Our thoughts and prayers are with the people of Jamaica," said Marvin Ellison, Lowe's chairman and CEO. "We believe in showing up to help when communities need it most. Through our nonprofit partners we aim to accelerate recovery efforts to help the island begin the long road to recovery."  

The direct hit from the powerful Category 5 hurricane left many Jamaican communities nearly demolished. Lowe's is working closely with its nonprofit partners on the ground in Jamaica to help meet urgent needs while also planning support for long-term recovery. Since the hurricane made landfall, Lowe's red vest associates have mobilized to deliver critical supplies to the island, including generators and flood relief buckets.

Visit Lowe's Newsroom for updates on Lowe's ongoing work to support recovery efforts.

About Lowe's

Lowe's Companies, Inc. (NYSE: LOW) is a FORTUNE® 100 home improvement company serving approximately 16 million customer transactions a week, with total fiscal year 2024 sales of more than $83 billion. Lowe's employs approximately 300,000 associates and operates over 1,700 home improvement stores, 530 branches and 130 distribution centers. Based in Mooresville, N.C., Lowe's supports the communities it serves through programs focused on creating safe, affordable housing, improving community spaces, helping to develop the next generation of skilled trade experts and providing disaster relief to communities in need. For more information, visit Lowes.com.  

Media Contact

Laurel Waller
Lowe's Companies, Inc.
[email protected]

SOURCE Lowe's Companies, Inc.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

The payments leader is making some big moves into AI, and the latest one is a big deal.

There has been no shortage of deals among artificial intelligence (AI) companies recently, with chipmakers, AI software developers, and other types of tech companies announcing big partnerships.

Well, PayPal (PYPL +2.00%) just joined the party. The online payments leader announced a deal with ChatGPT developer OpenAI to facilitate payments directly through the AI tool. But what could this mean to investors? Here's a rundown of the key points of the deal and what it could mean for the stock long-term.

PayPal's deal with OpenAI
First, here are the key points of PayPal's deal with OpenAI. The main idea is that PayPal will become the first digital wallet to be embedded into ChatGPT, which will enable users to pay for items they find through the platform.

We've seen several e-commerce companies announce deals to integrate their platforms with ChatGPT, including Etsy, Shopify, and Walmart. So, this deal will essentially let ChatGPT users who want to buy items use PayPal to complete the transaction without ever leaving ChatGPT.

Not only will this deal allow customers to pay for purchases with PayPal, but it will enable PayPal's millions of merchants to sell their products through the leading AI tool.

It's worth mentioning that fintech payment processor Stripe is also involved with OpenAI's Instant Checkout feature, specifically when it comes to allowing users to pay for Etsy purchases. But there are some big differences. Stripe is not a consumer-facing company -- it has no mobile app for consumers, and it cannot store funds on behalf of users. It's a payment tool, not a digital wallet. PayPal will be the first way to use stored funds to shop through ChatGPT.

What will this mean for PayPal investors?
It remains to be seen exactly what AI-powered shopping will ultimately look like or how quickly it will catch on, and it will almost certainly be an industry that evolves rapidly. But the general idea is that ChatGPT (and potentially other AI tools) can effectively serve as personal shoppers, helping users find the right products to meet their needs.

It's tough to overstate what a big win this deal is for PayPal. ChatGPT has more than 700 million weekly active users, several hundred million more than PayPal. This could potentially expose many new users to the PayPal ecosystem, drive increased engagement from existing users, and be a serious needle-mover for payment volume through the platform.

There's no way to quantify exactly what this could mean for PayPal investors, but it's fair to say that this is a big step in the right direction for the business. CEO Alex Chriss and his team have been hard at work over the past two years when it comes to focusing on efficiency and returning the company to profitable growth. This is the latest (and perhaps the most impressive) of several initiatives over the past year that could help earnings growth accelerate to management's 20%+ target over the next few years.

Strong results and profitability already
As a final thought, it's worth mentioning that PayPal announced the OpenAI partnership along with its third-quarter earnings, which were far stronger than investors had expected. Earnings per share grew by 12% year over year on an adjusted basis, payment volume grew 8% to more than $1.8 trillion annually, and the business generated $2.3 billion in free cash flow.

Despite the positive momentum and promising new initiatives like the OpenAI deal, PayPal trades for less than 14 times management's 2025 earnings guidance, and for an even lower multiple of free cash flow.

PayPal has been aggressively buying back its stock for the past couple of years, and it's easy to see why. This isn't just a legacy payments company -- it's at the forefront of agentic AI shopping. In addition to the OpenAI deal, PayPal recently announced a partnership with Alphabet's Google to develop commerce tools for use across its platforms. Buying shares before any of these recent developments start to impact the company's results could end up being a smart move.

Matt Frankel has positions in PayPal and Shopify and has the following options: short January 2027 $170 calls on Shopify. The Motley Fool has positions in and recommends Alphabet, Etsy, PayPal, Shopify, and Walmart. The Motley Fool recommends the following options: long January 2027 $42.50 calls on PayPal and short December 2025 $75 calls on PayPal. The Motley Fool has a disclosure policy.

Exxon is delivering strong earnings amid lower oil prices.

Crude prices have slumped this year. Brent oil, the global benchmark price, is currently in the mid-$60s, down about $10 a barrel from this time last year. While lower oil prices tend to negatively impact oil company earnings, ExxonMobil (XOM 0.29%) isn't your average oil producer.

That was abundantly clear in the oil giant's third-quarter financial results. ExxonMobil generated $7.5 billion, or $1.76 per share, of earnings during the period and $14.8 billion in cash flow from operations. That was the highest earnings per share the company has produced compared to similar oil price environments. Here's why Exxon is thriving amid lower oil prices.

Image source: Getty Images.

Drilling down into Exxon's third-quarter financial results
Exxon delivered record-setting production in Guyana and the Permian Basin. The oil giant started its fourth development in Guyana (Yellowtail), which came online four months early and under budget, boosting its average crude oil output to 700,000 barrels per day. Meanwhile, the company grew its production in the Permian Basin to 1.7 million barrels of oil equivalent (BOE) per day, fueled in part by the expanded use of proprietary technologies that are boosting well recoveries by up to 20%.

Yellowtail was one of eight major capital projects Exxon has started up this year. It has two more on track to come online by the end of 2025. "No one else in our industry is executing at this scale, with this level of innovation, or delivering this kind of value," stated CEO Darren Woods in the third-quarter earnings press release.

Today's Change

(

-0.29

%) $

-0.33

Current Price

$

114.36

Exxon also continues to execute its structural cost savings program. It has achieved an additional $2.2 billion of savings this year, pushing its cumulative total to $14 billion since launching this initiative in 2019. Exxon aims to increase the total to $18 billion by 2030. This cost-saving strategy enables Exxon to make more money at lower oil prices.

Exxon's strong financial results are allowing it to continue returning significant cash to shareholders. The oil giant returned $9.4 billion to investors via share repurchases and dividends. That brought its year-to-date total to $27.8 billion, comprising $12.9 billion in dividend payments and $14.9 billion in share repurchases. Even with those cash returns, Exxon maintained a fortress-like balance sheet. It boasts a sector-leading 9.5% net-debt-to-capital ratio, backed by a substantial $13.9 billion cash balance.

"ExxonMobil had a strong third quarter," stated CEO Darren Woods in the earnings press release, "continuing to demonstrate that we are truly in a league of our own."

Building toward an even better future
The energy giant continues to invest heavily to build an even better company. Capital spending totaled $8.6 billion in the quarter, including $2.4 billion in growth acquisitions. Exxon acquired an additional 80,000 net acres in the Permian Basin to expand its presence in this core area. Additionally, the company bought key assets from Superior Graphite, advancing its entry into the battery anode materials market.

The company is investing heavily to expand its upstream and downstream businesses. Exxon plans to increase its upstream oil and gas production to an average of 5.4 million BOE per day by 2030 (up from its current level of 4.7 million BOE per day). It aims to derive more than 60% of its future production from advantaged assets (its lowest-cost, highest-margin areas, such as the Permian and Guyana), up from the current level of 50%. Exxon is also investing significantly to expand its downstream product solutions businesses, which include refining, chemicals, and advanced materials. By 2030, Exxon aims to deliver $4.5 billion of annual earnings from this segment, up from $1.6 billion year-to-date.

Add the incremental earnings from these investments to the company's cost-savings initiatives, and Exxon expects to produce significantly higher earnings by 2030. That positions the company to continue returning more cash to investors. Exxon is on track to repurchase $20 billion of its shares this year and intends to buy back a similar amount next year. It also increased its dividend by another 4%, extending its growth streak to an industry-leading 43 consecutive years.

The best just keeps getting better
Exxon's strategy of investing heavily to grow its best assets while simultaneously stripping out structural costs is paying big dividends. The company is earning more money at lower oil prices. The oil giant plans to continue leaning into this strategy over the next five years, positioning it to produce even higher earnings in the future. Exxon's ability to thrive in any market environment makes it one of the best oil stocks to buy and hold for the long term.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in GOOGL over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Well-run real estate investment trusts (or REITs) can be some of the best dividend stocks in your portfolio.

IBM shares are outperforming Nvidia's in 2025 as the company sees its strongest revenue growth in years.

In 1997, IBM (IBM 0.85%) marked an AI milestone: Its Deep Blue program defeated reigning world chess champion Gary Kasparov, proving that brute force computing power could simulate human thinking. One grandmaster on the scene said that "the future of humanity is on the line," while Newsweek called it "the brain's last stand." The Wall Street Journal estimated that the match brought IBM $100 million worth of publicity.

It's hard to believe that this occurred before three of the "Magnificent Seven" companies were even founded, while a fourth, the AI juggernaut Nvidia (NVDA 0.04%), was years away from going public as a small-cap company. Today, 28 years after that AI triumph, some wonder if it's IBM that's making a "last stand" as the $15.7 trillion AI revolution unfolds.

Major AI savings and a quantum computing breakthrough
For decades, IBM could seemingly do no wrong. A 1985 New York Times article titled "The Daunting Power of IBM" reported that the company "of course, has been the No. 1 computer company virtually ever since the dawn of the computer age more than 30 years ago," and that IBM's hold on market share was so entrenched it raised antitrust concerns. The old office saying, "Nobody ever gets fired for buying IBM," reflected its computers' status as the gold standard. From its 1962 IPO to the dawn of the 21st century, IBM shares soared 3,800%.

In recent years, IBM has been an afterthought for investors, in the wake of its failure to capture a meaningful share in the $752 billion cloud market while Amazon and Microsoft carved out dominant positions. Even Warren Buffett took a capital loss on his shares of IBM when he sold in 2017, though dividends helped the investment squeak into positive return territory. The company was never considered among the Magnificent Seven tech giants soaring as they ushered in a new era.

Today's Change

(

-0.85

%) $

-2.65

Current Price

$

307.41

Yet shares of IBM are up 45% year to date, edging Nvidia's return of 42%. IBM stock is outperforming shares of the largest, most famous AI stock amid promising signs that its enterprise solutions for clients in the AI space is booming.

In March, IBM's CEO Arvind Krishna sat down with TIME magazine to explain his company's bet on smaller AI models, tailor-made for specific clients where accuracy is paramount, and management's 2020 decision not to build a large AI model in the mold of OpenAI's ChatGPT or Alphabet's Bard (later renamed Gemini). Explaining IBM's decision to eschew large, generalist AI models, he pointed out that they could be orders of magnitude more expensive while only being marginally more powerful, and that smaller models could be more accurate for specific client needs, saying, "If I'd like to control a blast furnace, it needs to be correct 100% of the time."

Six months later, there are signs that this decision is paying off. In Q3 2025, the company's "AI book of business," or the total value of its AI-related deals in software, hardware, and consulting, grew 26% year over year, from $7.5 billion to $9.5 billion. Software revenue rose 10%, while infrastructure revenue climbed 17%. Given the strength of these numbers, management raised its 2025 revenue growth outlook to over 5%.

While not a huge number, it comes as IBM improves margins, with its gross profit margin climbing 1.2% to 57.3%. The improving profitability comes as IBM expects to achieve $4.5 billion in annual savings from improved productivity, thanks to AI solutions, well ahead of the $2 billion annual savings goal set in 2023.

With IBM's AI solutions consulting segment growing by $1.5 billion in Q3, it stands to reason that the company itself would be a major beneficiary of new AI-driven efficiencies. IBM's own success in using its AI solution systems to save billions of dollars a year for itself can only help it grow its clientele in the AI software market sector, which is forecast to hit $467 million in 2030, up from $122 billion last year.

That's an average annual growth rate of 25%, which is slow compared to the 41% average annual growth expected for quantum computing through 2030. According to the research firm Marketsandmarkets, the sector will hit $20.2 billion by then, which makes IBM's latest feat in the sector noteworthy.

In "pole position" for the global quantum computing race?
On Friday, Reuters reported that IBM had developed an algorithm to correct quantum computing errors that can run on widely available semiconductor chips. Quantum computing, which can be used to solve mathematical problems that would take conventional computers thousands of years to solve, has been prone to errors that severely restrict the technology's usefulness for now. But according to Jay Gambetta, IBM's director of research, that's changing, with IBM's correction algorithm implementation being "10 times faster than what is needed." IBM shares surged more than 7% on the news.

According to Gambetta, IBM completed the algorithm a year ahead of schedule. By 2029, it plans to build a quantum computer called Starling. It's projected to run 20,000 times more operations than today's quantum computers, and could revolutionize industries like drug development and materials discovery by simulating how molecules react with speed and efficiency that's millions of times greater than that of quantum computers.

Last month, IBM unveiled Europe's first IBM Quantum system, marking its second installation outside the United States and the company's commitment to global leadership in quantum computing. Its existing global fleet of quantum computers, and recently inked partnership with the chipmaker Advanced Micro Devices to develop "quantum-centric supercomputers," has led The Wall Street Journal to conclude that IBM is in "pole position in a new race between Big Blue, Google, Microsoft, and a horde of start-ups."

So, is IBM a buy?
From growing revenue, improving margins, and leadership in what could be the next decade-defining tech story after AI, the path for IBM to reclaim its former glory looks clear.

Despite shares hitting an all-time high this week, the stock looks reasonably valued, with a price-to-earnings ratio of 24 that is well below the S&P 500 average of 31.

The company also pays a dividend yielding 2.2%, which is larger than that of any of the Magnificent Seven stocks, and its earnings have surprised analysts on the upside for each of the last four quarters.

It's very possible that IBM continues to be an afterthought in the battle for AI market share. But its billions of dollars in annual cost savings already realized in 2025 are a reminder that the global $15.7 trillion AI revolution just might be big enough for everyone. For investors seeking income, value, and a solid chance to back a rising industry leader, IBM is a buy.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

The article is for informational purposes only (not a solicitation or recommendation to buy or sell stocks). David is not a registered investment adviser. Investors should do their own research or consult a financial adviser to determine what investments are appropriate for their individual situation. This article expresses my opinions, and I cannot guarantee that the information/results will be accurate. Investing in stocks involves risk and could result in losses.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

These Marijuana Stocks Are Ready To Bounc

2 minute read

The Best Outlook For Profiting With Marijuana Stocks
Top cannabis companies are all awaiting the end of marijuana prohibtion. There has been a continuous battle to legalize cannabis to some degree federally. Many cannabis companies have made changes to prepare for what is to come. Most global regions that have legalized cannabis are working to meet the increased need for more cannabis products. This becomes possible through expanding and working on strategic partnerships to keep up as the cannabis industry evolves.

The bulk of what would help the industry worldwide is better laws and meeting the needs of small batch operators. As well as the bigger companies that deal more in volume. The quality of a product is important, and the better the cannabis product, the better the chances of building a stronger brand and loyal customer base. All of the above add more profits and value to the business, which ultimately plays a factor in whether people want to invest in marijuana stocks

The more research and planning you do, the better you can prepare if you are looking to invest in the best marijuana stocks. Even with all the market hurdles and lack of trading, the sector as a whole is thriving. So, when will the success of the business reflect in trading? That is the question many are left with as profits get taken when volatile pops in trading occur. For now, a good trading plan and patience are the systems many are taking with a focus on the long game as more developments happen. Below are a few marijuana stocks to watch in the stock market.

Cannabis Stocks For Better Gains

Green Thumb Industries Inc. (OTC:GTBIF)
Planet 13 Holdings Inc. (OTC:PLNH)

Green Thumb Industries Inc.
Green Thumb Industries Inc. manufactures, distributes, markets, and sells cannabis products for medical and adult-use in the United States. It operates through two segments, Retail and Consumer Packaged Goods.

In more recent news, the company has announced it is preparing to report its Q3 2025 earnings. On November 5th, 2025, after the market closes, Green Thumb has chosen to release its financial report for that time period.

Planet 13 Holdings Inc.
Planet 13 Holdings Inc., together with its subsidiaries, cultivates and provides cannabis and cannabis-infused products for medical and retail cannabis markets in the United States.

It is amazing to see the continuous growth and development of notable cannabis companies, and Planet 13 is one of them. Recently, the company has expanded its retail presence with the opening of a new dispensary in Pensacola, Florida.

[Read More] 3 Marijuana Stocks To Add To Your Portfolio Before The Next Bounce

Words From The Company
“We’re thrilled to expand our presence along Florida’s beautiful panhandle, and we look forward to serving patients in Pace and the nearby communities of Milton, Bagdad, and Avalon with Planet 13’s best-in-class cannabis products and unmatched customer service,” said Bob Groesbeck, Co-CEO of Planet 13.

MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | [email protected]

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in KURA over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Disclaimer: All investment opportunities carry inherent risk, including potential loss of principle. Carefully consider your investment objectives, level of experience and risk appetite before making any investment. The above discussion is a framework for investors (both long and short), to understand the factors that will move the underlying security’s price. It is not a prediction and should not be considered investment advice. KURA is a biotech stock and inherently a HIGH RISK investment.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

SummaryAmazon showcased the strength in the reacceleration of AWS, with >20% revenue growth and robust AI chip initiatives driving its cloud leadership.AMZN's e-commerce and advertising engines remain formidable, with automation and robotics poised to enhance margins and competitive edge.Despite AWS momentum, e-commerce's lower margins keep free cash flow under pressure, plausibly printing below 10% through 2027, tempering valuation optimism versus peers.With shares skimming near resistance and arguably already overbought, I finally downgrade AMZN to hold after two years, while we await another more delectable opportunity to add aggressively again. hapabapa/iStock Editorial via Getty Images

Amazon: AWS Gaining Clout Again The market has finally given the respect that the e-commerce monolith called Amazon (AMZN) truly deserves, as AMZN's Q3 earnings scorecard demonstrates its massive capabilities in

Analyst’s Disclosure:I/we have a beneficial long position in the shares of AMZN, NVDA either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

NEW YORK, Nov. 02, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of aTyr Pharma, Inc. (NASDAQ: ATYR) between January 16, 2025 and September 12, 2025, both dates inclusive (the “Class Period”), of the important December 8, 2025 lead plaintiff deadline.

SO WHAT: If you purchased aTyr Pharma common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the aTyr Pharma class action, go to https://rosenlegal.com/submit-form/?case_id=46109 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 8, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating false and misleading statements and/or concealing material adverse facts concerning the efficacy of Efzofitimod, particularly, the drug’s capability to allow a patient to completely taper their steroid usage. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the aTyr Pharma class action, go to https://rosenlegal.com/submit-form/?case_id=46109 call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com

U.S. Treasury Secretary Scott Bessent marked the 17th anniversary of the Bitcoin white paper with a bold statement that reignited the crypto policy debate in Washington. On October 31, Bessent posted on X (formerly Twitter) that Bitcoin “never shuts down,” a remark both praising the network's uptime and taking a subtle jab at Senate Democrats during the ongoing federal government shutdown.

Sun, 2/11/2025 - 11:26

Top trader DonAlt, who predicted XRP's 700% rally, says its calm at $2.5 is not luck — it is the "boomer base" effect. While zoomers chase hype coins, older holders keep XRP afloat and make it the market's most durable bet.

Cover image via U.Today

One of the most followed traders in crypto circles, known online as DonAlt, has once again turned heads by explaining why XRP has outperformed nearly every major altcoin in the current bear cycle.

The trader, known for his pinpoint prediction of the 700% rally from sub-$0.40 levels per XRP, believes the reason lies not in hype or liquidity, but in the holder base of the popular cryptocurrency.

DonAlt attributes recent XRP’s strength to a different demographic — older investors who treat the token as a long-term position rather than a short-term speculation so typical for "zoomers."

HOT Stories

Reason why XRP has been holding up better than the rest is the holder base IMO

XRP holders aren't the zoomer children jumping from coin to coin, it's the older folks that just like the thing and wanna own it

The zoomers run out of money while the longer term holders just chill

— DonAlt (@CryptoDonAlt) November 2, 2025 This older group tends to hold through chaotic crypto market volatility, largely ignoring social media trends and rotation cycles that dominate other digital assets. That behavior, according to DonAlt’s opinion, has kept XRP remarkably stable around $2.50 even as the wider altcoin market struggles.

Nonetheless, in a general market perspective, the trader is not that positive as he highlights that Bitcoin is flashing its first bearish signal since $88,000, Ethereum remains trapped under $4,000 and Solana is battling resistance near $210.

What's XRP price right now?As of now, against that backdrop, XRP’s bull structure remains valid, showing higher weekly closes and stable volume despite the ongoing market fatigue.

You Might Also Like

The takeaway is that conviction continues to outperform novelty. XRP’s long-term holder base has already weathered multiple full market cycles, from 2017 to the present, and its persistence has now become a structural advantage worth 700% at least for some of the investors.

In a market that rewards patience over hype, XRP still looks like one of the few assets built to endure, even though some may hate it and call it a useless "dino" coin.

Related articles

HASH and TRUMP have lost the most value daily.

Bitcoin’s relatively calm weekend price actions continued as the asset’s most significant gain came with a minor increase to $111,000, where it faced immediate resistance.

Most larger-cap alts are with minor losses over the past day, led by HYPE, BCH, HBAR, ZEC, and TAO.

BTC Stopped at $111K For Now
The primary cryptocurrency began the business week on the right foot, with a price surge to just over $116,000 on Monday. After a minor correction, it spiked above that line again on Tuesday, where it was stopped and pushed south hard.

On Wednesday, BTC had calmed at around $112,000 before the US Federal Reserve cut the interest rates for the second consecutive time in the past few months. Bitcoin reacted with an immediate price drop that drove it south to $110,000 and even lower on Thursday when the asset slipped below $106,500.

The bulls finally stepped up at this point and initiated a leg up that drove BTC up to $111,500. However, that was a short-term rally once again, and bitcoin has been unable to run higher since then. In the past few hours, it tried to overcome $111,000 but to no avail so far.

Its market cap has reclaimed the $2.2 trillion level on CG, while its dominance over the alts has stalled at 58%.

BTCUSD. Source: TradingView
Alts With Losses
As mentioned above, most larger-cap altcoins have marked minor losses over the past 24 hours. BNB, SOL, DOGE, TRX, ADA, XLM, and SUI are slightly in the red, while BCH has dropped by over 4%. HBAR, HYPE, and ZEC have declined by more than 2% daily.

In contrast, ETH, XRP, LINK, and AVAX have posted insignificant gains, while XMR has risen by over 3%, the same as ICP.

The two biggest losers on a daily scale are HASH (-7.5%) and TRUMP (-6.5%). Nevertheless, the meme coin related to the POTUS has jumped by 25% weekly.

The total crypto market cap has increased slightly overnight and is above $3.8 trillion.

Cryptocurrency Market Overview Daily. Source: QuantifyCrypto

Ethereum consolidates near $3,866 as bullish patterns form. Analysts see a potential $4,500 breakout by December 2025 if $4,000 resistance gives way.

XRP price is only 2% away from a key bullish zone between $2.52 and $2.54, where 1.56 billion XRP were last bought.Exchange outflows jumped 11.4%, showing falling selling pressure and renewed accumulation near this critical supply cluster.A daily close above $2.57 could lift XRP toward $2.81, while a drop below $2.38 would weaken the bullish setup.XRP entered November with little activity. The XRP price has been trading flat over the past 24 hours with a mild 0.6% gain at press time. While that may seem uneventful, the charts and on-chain data tell a different story.

A bullish pattern is tightening, selling pressure is falling, and XRP now sits 2% away from its “glory zone” — the level that could decide whether this calm start turns into something far bigger.

Sponsored

Sponsored

Cost Basis Heatmap and Exchange Data Set the StageThe cost basis distribution heatmap — a chart that shows where investors last bought XRP — highlights a dense cluster of holder activity between $2.52 and $2.54. This is the zone around which 1.56 billion XRP were last accumulated. These cost-heavy zones often act as barriers, as many holders sell when prices return to their buy level.

But this time, the market behavior is shifting.

Want more token insights like this? Sign up for Editor Harsh Notariya’s Daily Crypto Newsletter here.

XRP Supply Cluster: GlassnodeAccording to Glassnode, XRP’s exchange net position change — which tracks whether tokens are moving into or out of exchanges — fell from –866 million XRP on October 30 to –965 million XRP on November 1, marking an 11.4% increase in outflows.

Buyers Are Coming Back: GlassnodeThat means sellers are sending fewer coins into the exchanges, and more are being pulled into wallets for holding. Such rising outflows near a key resistance often signal accumulation, suggesting traders are expecting strength ahead rather than preparing to exit.

Sponsored

Sponsored

If XRP manages to clear the $2.54 zone, the next significant supply wall stands at a much higher level. That’s between $2.80 and $2.82, where another 1.87 billion XRP were last purchased.

A Higher XRP Supply Cluster: GlassnodeHowever, to go that high, the $2.54 level or the “glory zone” needs to give. That could then confirm the upside momentum. The XRP price chart, discussed next, also highlights that.

XRP Price Pattern Aligns With the 2% ThresholdThe technical chart adds to this narrative. On the 12-hour chart, XRP is forming a falling wedge — a pattern that usually signals a potential shift from decline to recovery. Prices are now testing the 0.382 Fibonacci retracement level at $2.50, almost touching the cost-basis zone noted earlier.

A daily close above $2.57 — roughly 2% higher than current levels — would confirm that buyers have cleared the near-term supply (between 2.52 and $2.54). The next key hurdle lies at $2.69, where the upper trendline of the wedge is located.

XRP Price Analysis: TradingViewIf the XRP price manages to stay above $2.69, it could open the door to $2.81, a higher cluster-zone marked on the heatmap. Sustained momentum beyond that may extend gains toward $3.10.

However, the XRP price setup has clear invalidation levels. A drop below $2.38, which is the 0.618 Fibonacci level, would weaken the bullish structure. Falling under $2.19 would further invalidate the bullishness, signaling that sellers have regained control.

Disclaimer

In line with the Trust Project guidelines, this price analysis article is for informational purposes only and should not be considered financial or investment advice. BeInCrypto is committed to accurate, unbiased reporting, but market conditions are subject to change without notice. Always conduct your own research and consult with a professional before making any financial decisions. Please note that our Terms and Conditions, Privacy Policy, and Disclaimers have been updated.

Journalist

Posted: November 2, 2025

Key Takeaways 
What’s next for Bitcoin’s price?
Per an analyst, an extended price range was likely to occur until OGs and LTH finish offloading.  

How’s the market positioned in the near-term? 
Options flows show mild bullish bias through November, but traders remain cautious heading into year-end.

Bitcoin [BTC] has become boring lately. As a perceived risk asset, you could easily predict its next direction by tracking the U.S equities and overall liquidity. 

But the crypto asset has shown random dislocation from the Nasdaq Composite and even gold. This has made it harder to gauge. 

In October, for example, gold had its moment; now Nasdaq has followed suit, but BTC continued to underperform, noted CryptoQuant’s Head of Research, Julio Moreno.  

Source: CryptoQuant

While the Nasdaq and gold printed new highs last month, BTC was in a pullback, shedding over $16,000 from $126,000 to $110,000. 

The results? BTC saw its first red “Uptober” since 2028. The sentiment has soured, unnerving a section of CT (Crypto Twitter), which feared that we could be entering the cyclical “bear phase.” 

‘IPO moment’ or consolidation phase?
However, others have made a contrarian bet- A consolidation instead of a “bear phase” into 2026. 

According to Jordi Visser, Analyst at 22V Research, BTC may be in its “IPO moment”, citing the OG distribution and drawing parallels to traditional initial public offerings (IPOs). 

Visser noted, 

“When a company goes public and early investors begin to sell their positions, the stock often consolidates, even during broader market rallies.”

The BTC OGs, who’ve held the asset for several years and other LTHs (long-term holders), have been dumping into the rally. 

In fact, LTHs have been offloading throughout H2, dumping 383K BTC (about $42B) in October alone, outpacing ETF demand.

Source: CryptoQuant

However, Visser said that the distribution doesn’t mean BTC is dying. In contrast, it’s a sign of maturity as treasuries and ETFs step in to offer exit liquidity for early investors, similar to IPOs. 

As a result, BTC could enter a consolidation phase, similar to those experienced by Facebook and Google after their IPOs. He added, 

“IPO distribution periods typically last 6-18 months. We’re probably several months into this process, but likely not done.”

Following the post-IPO consolidation, tech stocks rallied, Visser highlighted. His outlook was echoed by Bitwise CIO Matt Hougan, calling the projection an “accurate state of the BTC market.”

Options flows tilt bullish into November
That said, Options flows underscored bullish expectations into the end of November, but with a more cautious positioning towards year-end.

Notably, there were heavier call volumes (green bars) around $112K-$120K, suggesting bullish inclinations in the near term (end-November). 

Source: Arkham

However, in December, there was a slight uptick in put activity around $105,000, suggesting hedging or a cautious tone at year-end. 

XRP nears $2.60 resistance as traders await a breakout. A close above $2.72 could target $3.00, while a drop below $2.54 risks fall to $2.02.